JP2005519584A - Ｎｏｇｏレセプターホモログおよびそれらの使用 - Google Patents

Ｎｏｇｏレセプターホモログおよびそれらの使用 Download PDF

Info

Publication number
JP2005519584A
JP2005519584A JP2003538200A JP2003538200A JP2005519584A JP 2005519584 A JP2005519584 A JP 2005519584A JP 2003538200 A JP2003538200 A JP 2003538200A JP 2003538200 A JP2003538200 A JP 2003538200A JP 2005519584 A JP2005519584 A JP 2005519584A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
sequence
polynucleotide
ngrh1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003538200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519584A5 (https=
Inventor
カルメン・バルスケ
シュテファン・フレンツェル
アンドレアス・エドガル・ハイン
クレメンス・カウプマン
ベルント・ヨーゼフ・ゾンマー
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2005519584A publication Critical patent/JP2005519584A/ja
Publication of JP2005519584A5 publication Critical patent/JP2005519584A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
JP2003538200A 2001-10-22 2002-10-21 Ｎｏｇｏレセプターホモログおよびそれらの使用 Pending JP2005519584A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33759501P 2001-10-22 2001-10-22
PCT/EP2002/011757 WO2003035687A1 (en) 2001-10-22 2002-10-21 Nogo receptor homologues and their use

Publications (2)

Publication Number Publication Date
JP2005519584A true JP2005519584A (ja) 2005-07-07
JP2005519584A5 JP2005519584A5 (https=) 2006-01-05

Family

ID=23321175

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003538200A Pending JP2005519584A (ja) 2001-10-22 2002-10-21 Ｎｏｇｏレセプターホモログおよびそれらの使用

Country Status (4)

Country Link
US (3) US20050221420A1 (https=)
EP (1) EP1440091A1 (https=)
JP (1) JP2005519584A (https=)
WO (1) WO2003035687A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
NZ525422A (en) * 2000-10-06 2006-09-29 Biogen Idec Inc Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
PT1534736E (pt) 2002-08-10 2010-09-07 Univ Yale Antagonistas do receptor nogo
WO2005016955A2 (en) * 2003-08-07 2005-02-24 Biogen Idec Ma Inc. Nogo receptor antagonists
US7541335B2 (en) 2003-04-04 2009-06-02 University Of Rochester Nogo-receptors and methods of use
EP1615654A2 (en) * 2003-04-16 2006-01-18 Yale University Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
CA2555018A1 (en) * 2004-01-30 2005-08-18 Biogen Idec Ma Inc. Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists
US7973139B2 (en) * 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
WO2006047049A2 (en) * 2004-10-01 2006-05-04 Yale University Nogo-a polypeptide fragments, variant nogo receptor-1 polypeptides, and uses thereof
WO2006119013A2 (en) * 2005-04-29 2006-11-09 Wyeth Nogo receptor functional motifs and peptide mimetics related thereto and methods of using the same
US7893032B2 (en) * 2005-07-07 2011-02-22 Yale University NgR variants and compositions thereof for suppressing axonal growth inhibition
CN101248083A (zh) * 2005-08-25 2008-08-20 比奥根艾迪克Ma公司 Nogo受体多肽和多肽片段及其用途
CA2913655A1 (en) 2006-01-27 2007-08-09 Biogen Ma Inc. Nogo receptor antagonists
JP2009538282A (ja) * 2006-05-15 2009-11-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 乏突起膠細胞の生存を促進させるためのＮｏｇｏ受容体−１（ＮｇＲ１）アンタゴニストの使用
WO2007137303A2 (en) * 2006-05-24 2007-11-29 Myelin Repair Foundation, Inc. Permeability of blood-brain barrier

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215051A (en) * 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6043024A (en) * 1997-04-18 2000-03-28 Abbott Laboratories Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
NZ525422A (en) * 2000-10-06 2006-09-29 Biogen Idec Inc Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons

Also Published As

Publication number Publication date
EP1440091A1 (en) 2004-07-28
US20050221420A1 (en) 2005-10-06
WO2003035687A1 (en) 2003-05-01
US20090136970A1 (en) 2009-05-28
US20080090270A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
US20090136970A1 (en) Nogo receptor homologues and their use
US20080118951A1 (en) Nogo receptor homologues and their use
WO2001048189A1 (fr) Nouveaux recepteurs couples a une proteine de liaison au guanosine triphosphate, genes de ces derniers, et production et utilisation de ces derniers
JP2001506481A (ja) ブラジキニンｂ▲下１▼レセプターをコードするｄｎａ
JP2011115169A (ja) Ｋｃｎｂ：新規なカリウムチャネルタンパク質
JP2004500085A (ja) ヒトバニロイドレセプターｖｒ３をコードするｄｎａ
AU2005214141A1 (en) Protein ligands for NKG2d and UL16 receptors and uses thereof
US20060115816A1 (en) Splice variant cannabinoid receptor (cb1b)
EP1246914A2 (en) Nope polypeptides, encoding nucleic acids and methods of use
JP2002543762A (ja) ヒトｃｌａｘタンパク質およびその可溶性融合タンパク質をコードするｄｎａ分子
AU2001250794A1 (en) KCNB: a novel potassium channel protein
JP2002531112A (ja) 腫瘍壊死因子レセプターホモログ−１
JP2002153290A (ja) 新規ｕｎｃ５Ｈ４遺伝子及びそれにコードされる蛋白質
EP1618180A2 (en) Splice variants of human voltage-gated calcium channel alpha2delta-2 subunit designated-alpha2delta2-a and alpha2delta2-b
JP2000159798A (ja) 新規生理活性物質、その製造法および用途
JPWO2002062852A1 (ja) 細胞上に発現する受容体タンパク質
JP2003052384A (ja) 新規レセプタータンパク質及びそのｄｎａ
JPWO2001048188A1 (ja) 新規なグアノシン三リン酸結合蛋白質共役型の受容体およびそれらの遺伝子、並びにそれらの製造および用途
JPWO2001048189A1 (ja) 新規なグアノシン三リン酸結合蛋白質共役型の受容体およびそれらの遺伝子、並びにそれらの製造および用途
JPWO1999046378A1 (ja) 新規ｇ蛋白質共役型レセプター蛋白質
JP2003024075A (ja) 新規チロシンキナーゼ遺伝子及びそれにコードされるタンパク質
JP2003000253A (ja) 新規なｇタンパク質共役型受容体タンパク質及びその遺伝子
JP2002000280A (ja) 新規生理活性ペプチドおよびその用途
JP2003325185A (ja) Ｉｔｉｍモチーフを持つ新規な免疫機能抑制分子
JP2003265188A (ja) チンパンジープロスタグランジンｅ２受容体ｅｐ４サブタイプをコードするｄｎａ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081224